Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity
Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D, Thavendiranathan P. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity. JAMA Cardiology 2019, 4: 1007-1018. PMID: 31433450, PMCID: PMC6705141, DOI: 10.1001/jamacardio.2019.2952.Peer-Reviewed Original ResearchConceptsCancer therapy-related cardiac dysfunctionGlobal longitudinal strainLeft ventricular global longitudinal strainVentricular global longitudinal strainPrognostic valueCutoff valuePublication biasMeasurement of GLSNew-onset heart failure symptomsAbsolute global longitudinal strainWorse global longitudinal strainLarge prospective multicenter studyLeft ventricular ejection fractionDiscriminatory performanceLongitudinal strainChemotherapy-Induced CardiotoxicityGLS cutoff valueSubclinical ventricular dysfunctionHeart failure symptomsProspective multicenter studyVentricular ejection fractionCochrane Library databasesRisk of biasOptimal cutoff valueBetter prognostic performanceArtificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images.
Oikonomou E, Sangha V, Dhingra L, Aminorroaya A, Coppi A, Krumholz H, Baldassarre L, Khera R. Artificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images. Circulation Cardiovascular Quality And Outcomes 2024 PMID: 39221857, DOI: 10.1161/circoutcomes.124.011504.Peer-Reviewed Original ResearchCancer therapeutics-related cardiac dysfunctionGlobal longitudinal strainLeft ventricular systolic dysfunctionCardiac dysfunctionBreast cancerNon-Hodgkin lymphoma therapyNon-Hodgkin's lymphomaVentricular systolic dysfunctionAssociated with worse global longitudinal strainRisk stratification strategiesHigh-risk groupMonths post-treatmentPost hoc analysisElectrocardiographic (ECGTrastuzumab exposureLymphoma therapySystolic dysfunctionAI-ECGBefore treatmentRisk biomarkersLongitudinal strainLow riskStratification strategiesHigher incidencePositive screen